Improving lung cancer treatment with noninvasive imaging and blood tests
Official title: Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapy
Funded at Stanford University · NIH-11090525 · Data updated 2026-11-12
This study is looking to improve lung cancer treatment by finding better ways to see how well immunotherapy works for patients, helping doctors know early on who will benefit most from the treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | May 15, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $627,344 |
| NIH project number | 5R01CA290715-02 |
| Project ID | NIH-11090525 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced non-small cell lung cancer who are considering immunotherapy options.
✕Less likely to help
Patients with early-stage lung cancer or those who do not qualify for immunotherapy may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of immunotherapy for lung cancer patients by developing noninvasive imaging techniques and blood-based biomarkers. The goal is to identify which patients are likely to benefit from immune checkpoint inhibitors (ICIs) early in their treatment process. By utilizing advanced imaging and deep learning models, the study aims to provide more accurate predictions of treatment responses, addressing the limitations of current tissue-based biomarkers. This approach could lead to more personalized and effective treatment plans for patients with non-small cell lung cancer.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for lung cancer patients by enabling personalized immunotherapy strategies.
How similar studies have gone: Previous research has shown promise in using imaging and biomarkers for predicting treatment responses in cancer, suggesting that this approach could be effective.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Li, Ruijiang — Stanford University
- Study coordinator: Li, Ruijiang
Related research
Other NIH-funded projects on the same topics.
-
Biomarkers to predict and improve immunotherapy response in lung cancer
This grant aims to find gene-based markers that predict which NSCLC patients will benefit from immunotherapy and to uncover ways to make treatment work better for those who don’t respond.
-
Improving immunotherapy for lung cancer
A team at Emory University is exploring ways to boost how well PD-1–targeted therapies work for people with non-small cell lung cancer.
-
Targeting GARP-TGFβ to Improve Immunotherapy in NSCLC
A new antibody approach aims to block a key TGFβ-related pathway in the tumor environment to help people with non-small cell lung cancer respond better to therapy.
-
Targeting DHX9 to boost viral-like immune response in Small Cell Lung Cancer
A scientist team is testing whether blocking a protein called DHX9 can make aggressive small cell lung cancer more visible to the immune system and more responsive to immunotherapy.
-
Intratumoral microbiota and immune predictors of response to immunotherapy in lung cancer
A scientist team will study whether specific microbes inside lung tumors and immune cells can predict who will respond to immunotherapy in lung cancer.
-
Harnessing Exercise to Improve Immunotherapy for Lung Cancer
A clinical study tests whether a structured exercise program can boost how well lung cancer patients respond to immunotherapy and reduce treatment-related side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.